Clinical trials: HCV Infection
Hepatitis C, Hepatitis B
HBV/HCV/HIV in Belgian Prisons
To assess the prevalence of blood-borne viral infections in prisons in Belgium, screening will be executed in several prisons in Flanders, Brussels and Wallonia to obtain a geographical representative distribution.
- Conditions
- Hepatitis C, Hepatitis B, HIV Infections
- Trial name
- NCT04366492
- Testing
- Prevalence of blood borne viral infections (HBV/HCV/HIV)
- Where
- 2 sites in Belgium
- Volunteers
- 3,045 people, healthy volunteers welcome
- Sponsor
- Hasselt University
Hepatitis C
TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of increasing oral doses of TMC435350 after single and repeated dosing, followed by an open label repeated dosing session in 6 HCV genotype1…
- Trial name
- NCT00938899
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
The purpose of this study is to assess the safety, efficacy, and pharmacokinetics in a carefully monitored cohort of pediatric subjects infected with hepatitis C virus (HCV) on a telaprevir-based regimen in Part A and with dose…
- Trial name
- NCT01701063
- Testing
- Telaprevir, Peginterferon alfa-2b, Ribavirin
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 42 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatic Failure, Liver Failure
Cardiox Liver Function Test Pivotal Trial
Performance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum…
- Trial name
- LFT-0002 (NCT02552901)
- Testing
- 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Cardiox Corporation
Hepatitis C
Ribavirin, Its Dosing Regime
The purpose of this study is to determine if the medicines for chronic hepatitis C can be taken once daily, instead of twice daily.
- Trial name
- Ribados (NCT00484328)
- Testing
- Ribavirin
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Maastricht University Medical Center
Hepatitis C, Hepatitis C, Chronic
Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)
The goal of this study is to elucidate the reasons why patients with chronic hepatitis C (CHC) would not be considered eligible for antiviral treatment.
- Trial name
- NCT00724451
- Testing
- Peginterferon alfa-2b, Ribavirin, Peginterferon alfa-2a
- Volunteers
- 1,128 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease
RATIONALE: Studying samples of blood from patients with cancer, hepatitis C, or Crohn disease in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer and other…
- Trial name
- NCT00897312
- Testing
- infliximab, pegylated interferon alfa, ticilimumab
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Liver Fibrosis
Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis
Background: In patients with chronic liver diseases, liver fibrosis staging is crucial for hazard evaluation of future disease complication development and thus for the optimal decision making on treatment selections.In the era…
- Trial name
- ARFI (NCT01268865)
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- China Medical University Hospital
Chronic Hepatitis C Infection, Genotype 1
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
This is an open-label, randomized, safety, tolerability, dose-finding, PK/PD, and preliminary efficacy study of subcutaneous Hanferon™ in combination with ribavirin(RBV) in treatment-naïve subjects with genotype 1 hepatitis C.
- Trial name
- NCT01194037
- Testing
- recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Hepatitis C Virus Infection, Response to Therapy of, Drug Use
HCV Reinfection After DAA Therapy in PWID in Belgium
The primary aim of this study is to calculate the incidence of HCV reinfection after successful DAA treatment among people who have recently injected drugs.
- Trial name
- REINF_HCV (NCT04251572)
- Testing
- Blood sampling, questionaires
- Where
- 10 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Hasselt University
Hepatitis C
ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing
Hepatitis C virus (HCV) infection has become the leading fatal infectious disease in the United States. Approximately 75% of individuals who have been infected with HCV are chronically infected with the virus.
- Trial name
- NCT03767231
- Testing
- Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Hepatitis C, Chronic
Voices From the Black Community: Hepatitis C Research Participation
This is a one-time cross-sectional survey study of approximately 200 self-identified black or African-American patients who have had chronic hepatitis C viral infection (HCV) that will evaluate patients' willingness to…
- Trial name
- NCT04202081
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Hepatitis C
Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C
The purpose of this study is to evaluate the safety and efficacy of nitazoxanide-peginterferon alfa-2b combination therapy compared to peginterferon monotherapy in patients that are treatment naive or pre-treated for 24 weeks…
- Trial name
- NCT00418054
- Testing
- Nitazoxanide plus peginterferon alfa-2b, Peginterferon alfa-2b
- Where
- 2 sites in Egypt
- Volunteers
- 40 people
- Sponsor
- Romark Laboratories L.C.
Hepatitis C
Registry-based HCV Care Cascade Navigation at Atlanta's Grady Memorial Hospital
This study seeks to implement and evaluate a data-driven case navigation system for hepatitis C virus (HCV) treatment among persons who are either actively injecting drugs or who are receiving opioid substitution therapy (OST).
- Trial name
- EZ-C (NCT03441542)
- Testing
- Data-assisted Case Navigation, Standard of Care
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Opinion Research Center
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C
The interferon-free combination regimen of paritaprevir/ritonavir/ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- NCT02725866
- Testing
- Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin
- Volunteers
- 216 people
- Sponsor
- AbbVie
Chronic Hepatitis C, Insulin Resistance
Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance
The purpose of this study is to test whether the correction of insulin resistance with pioglitazone, will improve the response to antiviral treatment.
- Trial name
- PEGLIST C (NCT00927290)
- Testing
- Pioglitazone
- Where
- France
- Volunteers
- 40 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Chronic Hepatitis C, HCV
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C…
- Conditions
- Chronic Hepatitis C, HCV, Hepatitis C Virus
- Trial name
- NCT02692703
- Testing
- glecaprevir/pibrentasvir
- Volunteers
- 100 people
- Sponsor
- AbbVie
Hepatitis C
Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease.
-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) positron emission tomography (PET) is a imaging marker for presynaptic dopaminergic neuronal function.
- Trial name
- NCT04618679
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Hepatitis B Virus, HIV
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
This is a prospective HIV cohort that aims to establish causes of liver disease among HIV-infected individuals in Zambia, including viral hepatitis and alcohol.
- Conditions
- Hepatitis B Virus, HIV, Antiretroviral Therapy, Africa
- Trial name
- NCT02060162
- Testing
- Standard of care
- Where
- Zambia
- Volunteers
- 897 people
- Sponsor
- University of Alabama at Birmingham
Hepatitis C, Chronic
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
This 4 arm study is designed for patients with CHC who have not responded to peginterferon alfa-2b (12KD)/ribavirin combination therapy.
- Trial name
- NCT00087646
- Testing
- Ribavirin, peginterferon alfa-2a [Pegasys]
- Where
- 104 sites in United States, Belgium and 12 more
- Volunteers
- 948 people
- Sponsor
- Hoffmann-La Roche